ICU Medical Inc expected to post earnings of $1.00 a share - Earnings Preview

ICU Medical

06/08/2024 03:09

* ICU Medical Inc  ICUI.OQ   ICUI.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 7 for the
period ending January 1 0001
    * The San Clemente California-based  company is expected to
report
a 3.5% increase in revenue to $553.7 million from $535.11
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data. (December Majority Basis is
non-GAAP)
    * ​LSEG's mean analyst estimate for ICU Medical Inc is for
earnings of $1.00 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ICU Medical
Inc
is $135.50​, above​ its last closing price of $119.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.79        0.82       0.96      Beat    17.1
 Dec. 31 2024  1.19        1.19       1.57      Beat    31.7
 Sep. 30 2023  1.42        1.39       1.57      Beat    13.4​
 Jun. 30 2023  1.60        1.60       1.88      Beat    17.5
 ​​Mar.        1.44        1.43       1.74      Beat    22
 31 2023                                                
 Jan. 1 0001   1.60        1.56       1.60      Beat    2.6​
 Sep. 30 2022  1.48        1.46       1.75      Beat    19.6
 Jun. 30 2022  1.65        1.66       1.37      Missed  -17.5
 This summary was machine generated August 6 at 02:08 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)